Vista Capital Partners Inc. Makes New $5.34 Million Investment in Stryker Corporation $SYK

Vista Capital Partners Inc. acquired a new position in Stryker Corporation (NYSE:SYK – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 19,405 shares of the medical technology company’s stock, valued at approximately $5,344,000. Stryker accounts for approximately 0.5% of Vista Capital Partners Inc.’s portfolio, making the stock its 15th largest holding.

A number of other institutional investors also recently bought and sold shares of the company. Gables Capital Management Inc. purchased a new position in Stryker in the second quarter worth about $25,000. Kilter Group LLC bought a new stake in shares of Stryker during the 2nd quarter valued at about $25,000. Highland Investment Advisors LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at about $25,000. Cornerstone Financial Management LLC increased its position in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Finally, Compass Financial Management LLC purchased a new stake in shares of Stryker during the 2nd quarter valued at about $27,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $309.05 on Monday. The business has a 50-day simple moving average of $292.30 and a two-hundred day simple moving average of $322.60. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60. Stryker Corporation has a 52 week low of $267.00 and a 52 week high of $389.33. The stock has a market cap of $117.65 billion, a price-to-earnings ratio of 32.91, a PEG ratio of 2.13 and a beta of 0.78.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.19 earnings per share. On average, analysts expect that Stryker Corporation will post 14.85 EPS for the current year.

Insiders Place Their Bets

In other Stryker news, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 550,000 shares of the stock in a transaction on Friday, November 6th. The stock was sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the completion of the sale, the director directly owned 1,701,375 shares of the company’s stock, valued at approximately $553,491,315. This trade represents a 24.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 901,267 shares of company stock worth $297,123,701. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. BTIG Research dropped their price objective on shares of Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a report on Friday, October 30th. JPMorgan Chase & Co. cut their target price on shares of Stryker from $350.00 to $340.00 and set an “overweight” rating for the company in a research report on Friday, October 30th. Leerink Partners reduced their target price on shares of Stryker from $403.00 to $353.00 and set an “outperform” rating for the company in a report on Friday, October 9th. UBS Group decreased their price target on shares of Stryker from $400.00 to $382.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Finally, Evercore lifted their price target on shares of Stryker from $335.00 to $355.00 in a research note on Wednesday, October 28th. Twenty-one analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $342.19.

Read Our Latest Research Report on Stryker

Stryker Company Profile

(Free Report)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Further Reading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.